Home - Chinese Journal of Cancer Research

2023 Impact Factor of CJCR: 7
Journal Citation Reports ™, Clarivate Analytics

National Health Commission guidelines for diagnosis and treatment of colorectal cancer 2023 in China (English version)

National Health Commission of the People’s Republic of China; Society of Oncology, Chinese Medical Association

Stomach cancer burden in China: Epidemiology and prevention

In 2020, stomach cancer was the fifth most commonly diagnosed cancer and the fourth leading cause of cancer-related death worldwide. Due to the relatively huge population base and the poor survival rate, stomach cancer is still a threat in China, and accounts for nearly half of the cases worldwide. Fortunately, in China, the incidence and mortality rates of stomach cancer presented a declining trend owing to the change of individual life styles and the persistent efforts to prevent stomach cancer from the governments at all levels. Helicobacter pylori (H. pylori) infection, poor eating habits, smoking, history of gastrointestinal disorders, and family history of stomach cancer are the main risk factors for stomach cancer in China. As a result, by taking risk factors for stomach cancer into account, specific preventive measures, such as eradicating H. pylori and implementing stomach cancer screening projects, should be taken to better prevent and decrease the burden of stomach cancer.

Burden of liver cancer: From epidemiology to prevention

In this review, we offer a concise overview of liver cancer epidemiology in China and worldwide from the official databases of GLOBOCAN 2020 and the National Cancer Registry in China. We also summarized the evidence for the main risk factors associated with liver cancer risk and discuss strategies implemented in China to control the liver cancer burden. Overall, liver cancer was the sixth most commonly diagnosed cancer and the third leading cause of cancer-related death worldwide in 2020. Although China contributed to nearly half of cases across the world alone, the incidence and mortality rates of liver cancer presented a declining trend owing to the persistent efforts from the governments at all levels. The current liver cancer burden in China still faces an arduous challenge due to the relatively large population base as well as the substantially low survival rate (12.1%). To better control the liver cancer burden with the lowest cost, specific measures should be conducted by reducing exposure to established risk factors such as hepatitis B infection and aflatoxin.

‹ ›

Vol 36, No 6 (Dec 2024)

Research Highlight

Recent advances in systematic therapy of breast cancer: Chinese contribution for international progress

Yan Wang, Binghe Xu

Pages: 587-591 HTML

Advances in gastric cancer treatment in 2024: Key breakthroughs and emerging trends

Jingtao Wei, Zhaode Bu

Pages: 592-595 HTML

Microbiota and urinary tumor immunity: Mechanisms, therapeutic implications, and future perspectives

Dengxiong Li, Ruicheng Wu, Qingxin Yu, Zhouting Tuo, Jie Wang, Koo Han Yoo, Wuran Wei, Yubo Yang, Luxia Ye, Yiqing Guo, Premkamon Chaipanichkul, Uzoamaka Adaobi Okoli, Toryn M Poolman, Jeremy P Burton, William C. Cho, Susan Heavey, Dechao Feng

Pages: 596-615 HTML

Review Article

Myeloid cells meet CD8⁺T cell exhaustion in cancer: What, why and how

Yijie Zhai, Xiaoting Liang, Mi Deng

Pages: 616-651 HTML

Fatty acid metabolism: A new target for nasopharyngeal carcinoma therapy

Juan Li, Pengbin Ping, Yanhua Li, Xiaoying Xu

Pages: 652-668 HTML

Role of lysine-specific demethylase 1 in immunotherapy of gastric cancer: An update

Yongjing Ren, Yanan Gong, Huan Zhao, Duo You, Zhifei Li, Sai-Qi Wang, Xiaobing Chen

Pages: 669-682 HTML

Intratumor microbiota and colorectal cancer: Comprehensive and lucid review

Zhen Zong, Wenjuan Zeng, Yin Li, Menghui Wang, Yuke Cao, Xifu Cheng, Zhenhua Jin, Shengxun Mao, Xingen Zhu

Pages: 683-699 HTML

Original Article

Distinctive role of DICER1 mutations in distant metastatic thyroid cancer

Cong Shi, Zhuanzhuan Mu, Wenting Guo, Xin Zhang, Di Sun, Yuqing Sun, Hao Wang, Dingding Zhang, Jun Liang, Yansong Lin

Pages: 700-712 HTML

Efficacy, safety, and multi-omics analysis of pembrolizumab combined with nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: A single-arm phase 2 study

Lin Gui, Xinrui Chen, Wen Zhang, Zucheng Xie, Yu Zhang, Weihua Li, Tongji Xie, Jiarui Yao, Haohua Zhu, Le Tang, Jianliang Yang, Peng Liu, Yan Qin, Changgong Zhang, Xiaohui He, Yuankai Shi

Pages: 713-728 HTML

HER2-low status improves prognosis prediction in breast cancer patients receiving neoadjuvant treatment: A comparison of pathological stage, modified CPS+EG scoring system, and Neo-Bioscore

Yujie Lu, Siji Zhu, Chenghui Wu, Xiaochun Fei, Kunwei Shen, Xiaosong Chen

Pages: 729-741 HTML

National validation of laparoscopic approach for locally advanced gastric cancer: Comparison of a randomized controlled trial and real-world practice results

Bang Wool Eom, Mira Han, Hong Man Yoon, Woo Jin Hyung, Han-Kwang Yang, Young-Kyu Park, Hyuk-Joon Lee, Ji Yeong An, Wook Kim, Hyoung-Il Kim, Hyung-Ho Kim, Seung Wan Ryu, Hoon Hur, Min-Chan Kim, Seong-Ho Kong, Gyu Seok Cho, Jin-Jo Kim, Do Joong Park, Young-Woo Kim, Jong Won Kim, Joo-Ho Lee, Sang-Uk Han, Keun Won Ryu, the information committee of the Korean Gastric Cancer Association

Pages: 742-751 HTML

Global, regional, and national burden of colorectal cancer, 1990−2021: An analysis from global burden of disease study 2021

Jiachen Wang, Siyi He, Mengdi Cao, Yi Teng, Qianru Li, Nuopei Tan, Yujie Wu, Tingting Zuo, Tianyi Li, Yuanjie Zheng, Changfa Xia, Wanqing Chen

Pages: 752-767 HTML

Long-term survival outcomes of laparoscopic surgery in patients with colorectal cancer: A propensity score matching retrospective cohort study

Ruoxi Tian, Jiyun Li, Fei Huang, Pu Cheng, Mandoula Bao, Liming Zhao, Zhaoxu Zheng

Pages: 768-780 HTML

CSCO Guidelines

CSCO guidelines for colorectal cancer version 2024: Updates and discussions

Liubo Chen, Hanguang Hu, Ying Yuan, Shanshan Weng

Pages: 233-239 HTML

CSCO guidelines for colorectal cancer version 2023: Updates and insights

Mi Mi, Shanshan Weng, Ziheng Xu, Hanguang Hu, Yi Wang, Ying Yuan

Pages: 233-238 HTML

CSCO guidelines for colorectal cancer version 2022: Updates and discussions

Zhijun Yuan, Shanshan Weng, Chenyang Ye, Hanguang Hu, Suzhan Zhang, Ying Yuan

Pages: 67-70 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)

Jun Zhu, Jun Ma, Union for China Lymphoma Investigators of Chinese Society of Clinical Oncology

Pages: 289-301 HTML

Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020

Caixia Dong, Yuwei Ding, Shanshan Weng, Guichao Li, Yanqing Huang, Hanguang Hu, Zhen Zhang, Suzhan Zhang, Ying Yuan

Pages: 302-307 HTML

Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019

Shanshan Weng, Ying Yuan, Xicheng Wang, Gong Chen, Yi Wang, Weiqi Sheng, Xinxiang Li, Aiping Zhou, Zhen Zhang, Guichao Li, Sanjun Cai, Ruihua Xu, Jin Li, Suzhan Zhang

Pages: 403-407 HTML

Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018

Ying Yuan, Xicheng Wang, Gong Chen, Yi Wang, Weiqi Sheng, Xinxiang Li, Aiping Zhou, Zhen Zhang, Guichao Li, Sanjun Cai, Ruihua Xu, Jin Li, Suzhan Zhang

Pages: 423-425 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer working group

Pages: 84-98 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer working group

Pages: 99-116 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer working group

Pages: 117-134 HTML

NHCPRC Guidelines

National Health Commission guidelines for diagnosis and treatment of colorectal cancer 2023 in China (English version)

National Health Commission of the People’s Republic of China; Society of Oncology, Chinese Medical Association

Pages: 197-232 HTML